Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non–Small Cell Lung Cancer

被引：0
|
作者：
Mitsugu Ikeda
Tatsuya Ochibe
Masahiro Tohkin
机构：
[1] Nagoya City University,Department of Regulatory Science, Graduate School of Pharmaceutical Sciences
来源：
Therapeutic Innovation & Regulatory Science | 2019年 / 53卷
关键词：
phase 3 clinical trial; systematic review; non—small cell lung cancer; primary endpoint; success rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：324 / 331
页数：7
相关论文
共 50 条
  • [31] Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?
    Cai, Jing-Sheng
    Li, Yun
    Wang, Xun
    BMC CANCER, 2023, 23 (01)
  • [32] Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials
    Zhang, Xiao-Nan
    Huang, Lei
    ONCOTARGET, 2017, 8 (52) : 90327 - 90337
  • [33] Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?
    Jing-Sheng Cai
    Yun Li
    Xun Wang
    BMC Cancer, 23
  • [34] Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials
    Chen, Kaiqi
    Wang, Xinwei
    Yue, Rui
    Chen, Wei
    Zhu, Danping
    Cui, Shikui
    Zhang, Xijian
    Jin, Zhao
    Xiao, Tong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [35] The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials
    Amin Daei Sorkhabi
    Mahta ZareDini
    Asra Fazlollahi
    Aila Sarkesh
    Amirreza Naseri
    Seyed Ehsan Mousavi
    Seyed Aria Nejadghaderi
    Mark J M Sullman
    Ali-Asghar Kolahi
    Saeid Safiri
    BMC Pulmonary Medicine, 23
  • [36] Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials
    He, Xuan
    Wang, Ji
    Li, Yuanmin
    ONCOTARGETS AND THERAPY, 2015, 8 : 2023 - 2031
  • [37] Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer
    Cheema, P. K.
    Burkes, R. L.
    CURRENT ONCOLOGY, 2013, 20 (02) : E150 - E160
  • [38] Brain Metastases as the Primary Site of Relapse in Two Randomized Phase III Pemetrexed Trials in Advanced Non-Small-Cell Lung Cancer
    Ortuzar, Waldo
    Hanna, Nasser
    Pennella, Eduardo
    Peng, Guangbin
    Langer, Corey
    Monberg, Matthew
    Scagliotti, Giorgio
    CLINICAL LUNG CANCER, 2012, 13 (01) : 24 - 30
  • [39] The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
    Xu, Yangyang
    Wang, Qin
    Xie, Jingyuan
    Chen, Mo
    Liu, Hongbing
    Zhan, Ping
    Lv, Tangfeng
    Song, Yong
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [40] Efficacy of preoperative pulmonary rehabilitation in lung cancer patients: a systematic review and meta-analysis of randomized controlled trials
    Guo, Yalun
    Pan, Mengdie
    Xiong, Meidi
    Liu, Miao
    Zhu, Na
    Dong, Haoxu
    Zhang, Chunhua
    DISCOVER ONCOLOGY, 2025, 16 (01)
12345